Citadel Advisors
TCON

Citadel Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Citadel Advisors’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-999
Closed -$37.8K – 15465
2023
Q1 		$37.8K Buy
999
+919
+1,149% +$30.1K ﹤0.01% 12492
2022
Q4 		$2.37K Sell
80
-961
-92% -$29.1K ﹤0.01% 14346
2022
Q3 		$35K Buy
+1,041
New +$39.7K ﹤0.01% 11829
2022
Q2 		– Sell
-2,487
Closed -$96.3K – 14419
2022
Q1 		$131K Buy
2,487
+1,398
+128% +$70.3K ﹤0.01% 12005
2021
Q4 		$60K Sell
1,089
-734
-40% -$46.8K ﹤0.01% 13148
2021
Q3 		$141K Buy
1,823
+1,160
+175% +$98.2K ﹤0.01% 12447
2021
Q2 		$86K Sell
663
-59
-8% -$8.16K ﹤0.01% 13036
2021
Q1 		$119K Buy
722
+106
+17% +$20.4K ﹤0.01% 12306
2020
Q4 		$144K Buy
+616
New +$85.7K ﹤0.01% 9975
2020
Q3 		– Sell
-1,238
Closed -$49K – 10911
2020
Q2 		$49K Buy
+1,238
New +$49K ﹤0.01% 9318
2020
Q1 		– Sell
-802
Closed -$38K – 10338
2019
Q4 		$38K Buy
802
+636
+383% +$41.8K ﹤0.01% 8820
2019
Q3 		$15K Buy
166
+103
+163% +$10.6K ﹤0.01% 9002
2019
Q2 		$9K Buy
+63
New +$9.96K ﹤0.01% 9045
2019
Q1 		– Sell
-132
Closed -$17K – 10013
2018
Q4 		$17K Buy
132
+29
+28% +$7.87K ﹤0.01% 8808
2018
Q3 		$42K Buy
+103
New +$47.7K ﹤0.01% 8838
2018
Q1 		– Sell
-99
Closed -$66K – 8912
2017
Q4 		$66K Buy
+99
New +$59.8K ﹤0.01% 7552

Other funds holding TCON

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's TCON Position: Q2 2023 in Review

Citadel Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2023, closing a stake of 999 shares — an estimated $37.8K sold.

Citadel Advisors first reported a position in TCON in Q4 2017 and held it in 16 quarters. The position peaked at $144K in Q4 2020. 27 funds tracked by Wall St. Rank hold TCON as of Q2 2023.

  • Citadel Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Citadel Advisors sold 999 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $37.8K.
  • Citadel Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 16 quarters.
  • Citadel Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $144K in Q4 2020.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.